T1DM Therapeutics in Major Developed Markets Forecast to Year 2021 3 | Page 6

6.1 Licensing Deals 119
6.1.1 ViaCyte Enters into Option for Licensing Agreement with Janssen Research & Development
124
6.1.2 Eli Lilly Enters into Licensing Agreement with MacroGenics 124
6.1.3 Bayhill Therapeutics Enters into Licensing Agreement with Genentech 124
6.1.4 King's College Enters into Licensing Agreement with UCB 124
6.1.5 Nuvilex Enters into Licensing Agreement with University of Technology Sydney 125
6.1.6 Sanofi Enters into Licensing Agreement with MannKind for Afrezza 125
6.1.7 Eli Lilly Enters into Licensing Agreement with Adocia 125
6.2 Co-development Deals 126
6.2.1 GlaxoSmithKline Signs Partnership Agreement with Tolerx 131
6.2.2 Diamyd Medical Enters into Co-Development Agreement with Ortho-McNeil-Janssen 131
6.2.3 Osiris Therapeutics Enters into an Agreement with Juvenile Diabetes Research Foundation
International 131
6.2.4 Transition Therapeutics Enters into Co-Development Agreement with Juvenile Diabetes
Research Foundation 131
6.2.5 BioLineRx Enters into Co-Development Agreement with JHL Biotech 132
7 Appendix 133
7.1 All Pipeline Drugs by Phase of Development 133
7.1.1 Discovery 133
7.1.2 Preclinical 134
7.1.3 IND/CTA-filed 137
7.1.4 Phase I 138
7.1.5 Phase II 139
7.1.6 Phase III 140
7.1.7 Pre-registration 140